The stock of MAIA Biotechnology Inc (AMEX: MAIA) has increased by 9.44 when compared to last closing price of 1.8.MAIA Biotechnology Inc (AMEX: MAIA)’s stock price has plunge by 9.44relation to previous closing price of 1.8. Despite this, the company has seen a gain of 13.22% in its stock price over the last five trading days. https://www.marketscreener.com reported 2025-06-26 that MAIA Biotechnology, Inc entered into a stock purchase agreement at maximum of 337,876 shares at a price $1.74 per share for gross proceeds $5,87,904.24 on June 26, 2025. The transaction included participation from Prevail Partners, LLC. The transaction will be in tranches.The transaction upfront payment of $58,800.3333 of Shares and 36 equal payments of $14,697.33.
Is It Worth Investing in MAIA Biotechnology Inc (AMEX: MAIA) Right Now?
MAIA Biotechnology Inc (AMEX: MAIA) has a higher price-to-earnings ratio of N/Ax compared to its average ratio, The 36-month beta value for MAIA is at 0.05. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The average price suggested by analysts for MAIA is N/A, which is -$296066.0 below the current market price. The public float for MAIA is 21.93M, and currently, shorts hold a 1.80% of that float. The average trading volume for MAIA on July 01, 2025 was 296.08K shares.
MAIA’s Market Performance
MAIA’s stock has seen a 13.22% increase for the week, with a 10.06% rise in the past month and a 28.76% gain in the past quarter. The volatility ratio for the week is 6.71%, and the volatility levels for the past 30 days are at 6.26% for MAIA Biotechnology Inc The simple moving average for the past 20 days is 10.80% for MAIA’s stock, with a -4.96% simple moving average for the past 200 days.
Analysts’ Opinion of MAIA
Many brokerage firms have already submitted their reports for MAIA stocks, with N/A repeating the rating for MAIA by listing it as a “N/A.” The predicted price for MAIA in the upcoming period, according to N/A is N/A based on the research report published on N/A of the N/A year N/A.
N/A, on the other hand, stated in their research note that they expect to see MAIA reach a price target of N/A. The rating they have provided for MAIA stocks is “N/A” according to the report published on N/A.
N/A gave a rating of “N/A” to MAIA, setting the target price at N/A in the report published on N/A of the N/A year.
MAIA Trading at 5.70% from the 50-Day Moving Average
After a stumble in the market that brought MAIA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.54% of loss for the given period.
Volatility was left at 6.26%, however, over the last 30 days, the volatility rate increased by 6.71%, as shares surge +12.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +26.45% upper at present.
During the last 5 trading sessions, MAIA rose by +12.64%, which changed the moving average for the period of 200-days by -37.38% in comparison to the 20-day moving average, which settled at $1.7775. In addition, MAIA Biotechnology Inc saw -40.84% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MAIA starting from Smith Stan, who purchase 33,333 shares at the price of $1.50 back on Jun 03 ’25. After this action, Smith Stan now owns 1,305,059 shares of MAIA Biotechnology Inc, valued at $50,000 using the latest closing price.
Guerrero Ramiro, the Director of MAIA Biotechnology Inc, purchase 20,000 shares at $1.50 during a trade that took place back on May 08 ’25, which means that Guerrero Ramiro is holding 588,218 shares at $30,000 based on the most recent closing price.
Stock Fundamentals for MAIA
Current profitability levels for the company are sitting at:
- N/A for the present operating margin
- N/A for the gross margin
The net margin for MAIA Biotechnology Inc stands at N/A. The total capital return value is set at -2.71. Equity return is now at value -1131.02, with -191.48 for asset returns.
Based on MAIA Biotechnology Inc (MAIA), the company’s capital structure generated N/A points at debt to capital in total, while cash flow to debt ratio is standing at N/A. The debt to equity ratio resting at N/A. The interest coverage ratio of the stock is -216867.82.
Currently, EBITDA for the company is -16.96 million with net debt to EBITDA at 0.53. When we switch over and look at the enterprise to sales, we see a ratio of N/A. The receivables turnover for the company is N/Afor trailing twelve months and the total asset turnover is N/A. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.35.
Conclusion
In conclusion, MAIA Biotechnology Inc (MAIA) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
